Benefits of statin therapy and compliance in high risk cardiovascular patients.
Benefits of statin therapy and compliance in high risk cardiovascular patients.
复制标题
DOI：
10.2147/vhrm.s9474
复制
发表时间：
2010-10-05
影响因子：
2.9
通讯作者：
Deedwania PC
中科院分区：
文献类型：
--
作者：
Lardizabal JA;Deedwania PC
心血管疾病(CVD)仍然是全球死亡的头号原因。有相当多的证据支持他汀类药物在冠心病(CHD)和中风的一级和二级预防环境中的死亡率和发病率益处。也有数据指出他汀类药物在其他高危心血管疾病中的优势，如糖尿病、慢性肾脏病、CHF和PVD。治疗这些心血管疾病的国家和国际临床指南都主张在适当的患者中使用他汀类药物。然而，他汀类药物治疗的总体依从性仍然不佳。与病人、医生和经济相关的因素都起到了作用。在设计方法以提高对基于指南的治疗的依从性时，需要考虑这些因素。为了充分获得他汀类药物治疗的好处，应该鼓励在现实世界环境中改善长期治疗依从性的干预措施。
Cardiovascular disease (CVD) remains the top cause of global mortality. There is considerable evidence that supports the mortality and morbidity benefit of statin therapy in coronary heart disease (CHD) and stroke, both in primary and secondary prevention settings. Data also exist pointing to the advantage of statin treatment in other high-risk CVD conditions, such as diabetes, CKD, CHF, and PVD. National and international clinical guidelines in the management of these CVD conditions all advocate for the utilization of statin therapy in appropriate patients. However, overall compliance to statin therapy remains suboptimal. Patient-, physician-, and economic-related factors all play a role. These factors need to be considered in devising approaches to enhance adherence to guideline-based therapies. To fully reap the benefits of statin therapy, interventions which improve long-term treatment compliance in real-world settings should be encouraged.